tiprankstipranks
Advertisement
Advertisement

RGNX Stock Latest News

Shareholders Sue RGNX Over Gene Therapy Study Claims
Market NewsShareholders Sue RGNX Over Gene Therapy Study Claims
16d ago
RGNX
RegenXBio Reaches Settlement with GSK Over License Fees
PremiumCompany Announcements
RegenXBio Reaches Settlement with GSK Over License Fees
20d ago
8K
RGNX
REGENXBIO Faces Federal Securities Lawsuit Over Allegedly Concealed Gene Therapy Safety Risks
PremiumClass Action
REGENXBIO Faces Federal Securities Lawsuit Over Allegedly Concealed Gene Therapy Safety Risks
29d ago
RGNX
Regenxbio reports interim data from Phase I/II AFFINITY DUCHENNE trial
PremiumThe Fly
Regenxbio reports interim data from Phase I/II AFFINITY DUCHENNE trial
29d ago
RGNX
Regenxbio price target lowered to $30 from $32 at H.C. Wainwright
PremiumThe Fly
Regenxbio price target lowered to $30 from $32 at H.C. Wainwright
1M ago
RGNX
Controversial Prasad leaving FDA, NYT reports
PremiumThe FlyControversial Prasad leaving FDA, NYT reports
1M ago
AZN
BMY
RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty
Premium
Company Announcements
RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty
1M ago
RGNX
Buy These 3 Best Stocks Now, According to Top Wall Street Analysts, 3/6/2026
Premium
Market News
Buy These 3 Best Stocks Now, According to Top Wall Street Analysts, 3/6/2026
1M ago
MGX
HELP
RegenXBio Earnings Call Balances Gene Therapy Risks
PremiumCompany Announcements
RegenXBio Earnings Call Balances Gene Therapy Risks
1M ago
RGNX
Regenxbio price target lowered to $17 from $18 at Morgan Stanley
PremiumThe Fly
Regenxbio price target lowered to $17 from $18 at Morgan Stanley
1M ago
RGNX
RegenXBio: Undervalued Multi‑Program Gene Therapy Story With Key RGX‑202 and RGX‑314 Catalysts Supporting a Buy Rating
PremiumRatings
RegenXBio: Undervalued Multi‑Program Gene Therapy Story With Key RGX‑202 and RGX‑314 Catalysts Supporting a Buy Rating
1M ago
RGNX
Regenxbio price target lowered to $42 from $45 at Stifel
PremiumThe Fly
Regenxbio price target lowered to $42 from $45 at Stifel
1M ago
RGNX
Regenxbio reports Q4 EPS ($1.30) vs. ($1.01) last year
PremiumThe FlyRegenxbio reports Q4 EPS ($1.30) vs. ($1.01) last year
1M ago
RGNX
FDA review process for accelerated approval narrows, less predictable, WSJ says
Premium
The Fly
FDA review process for accelerated approval narrows, less predictable, WSJ says
1M ago
CAPR
IRON
RGNX Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
RGNX Earnings this Week: How Will it Perform?
1M ago
RGNX
LEVI & KORSINSKY, LLP: RGNX DISCLOSURE TIMELINE REVEALS PATTERN OF ALLEGED INVESTOR HARM
PremiumClass Action
LEVI & KORSINSKY, LLP: RGNX DISCLOSURE TIMELINE REVEALS PATTERN OF ALLEGED INVESTOR HARM
1M ago
RGNX
When a Clinical Hold Disrupts a Gene Therapy Program: What Happened to Regenxbio Stock
PremiumClass Action
When a Clinical Hold Disrupts a Gene Therapy Program: What Happened to Regenxbio Stock
1M ago
RGNX
RegenXBio’s RGX-121 Hunter Syndrome Trial Faces Suspension: What Investors Should Know
PremiumCompany Announcements
RegenXBio’s RGX-121 Hunter Syndrome Trial Faces Suspension: What Investors Should Know
1M ago
RGNX
Stifel says uniQure ‘understandably’ under pressure on Makary comments
PremiumThe Fly
Stifel says uniQure ‘understandably’ under pressure on Makary comments
1M ago
QURE
RGNX
Why Is UniQure Stock Down 30% Today?
PremiumMarket NewsWhy Is UniQure Stock Down 30% Today?
1M ago
QURE
RGNX
Leerink says FDA remarks likely targeted Regenxbio, not uniQure’s program
Premium
The Fly
Leerink says FDA remarks likely targeted Regenxbio, not uniQure’s program
1M ago
QURE
RGNX
Is the SPDR S&P Biotech ETF (XBI) a ‘Strong Buy’ Right Now?
Premium
Market News
Is the SPDR S&P Biotech ETF (XBI) a ‘Strong Buy’ Right Now?
1M ago
XBI
ERAS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >